Last reviewed · How we verify
antibiotic of Investigator's choice
This antibiotic inhibits bacterial protein synthesis by binding to the bacterial ribosome.
This antibiotic inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Serious gram-negative bacterial infections (investigator's choice indication).
At a glance
| Generic name | antibiotic of Investigator's choice |
|---|---|
| Sponsor | Achaogen, Inc. |
| Drug class | Antibiotic |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As an investigator's choice antibiotic in phase 3 development by Achaogen, the drug likely represents a novel or semi-synthetic antibiotic targeting bacterial ribosomes or cell wall synthesis. Achaogen's pipeline has historically focused on novel antibiotics for serious gram-negative infections, particularly those resistant to standard therapies.
Approved indications
- Serious gram-negative bacterial infections (investigator's choice indication)
Common side effects
- Nausea
- Diarrhea
- Headache
- Injection site reactions
Key clinical trials
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (PHASE2)
- EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin (PHASE4)
- NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (PHASE3)
- Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer (PHASE2)
- A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) (PHASE3)
- Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (PHASE4)
- Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antibiotic of Investigator's choice CI brief — competitive landscape report
- antibiotic of Investigator's choice updates RSS · CI watch RSS
- Achaogen, Inc. portfolio CI